Oppenheimer reiterated coverage on Turning Point with a new price target
$TPTX
Biotechnology: Pharmaceutical Preparations
Health Care
Oppenheimer reiterated coverage of Turning Point with a rating of Outperform and set a new price target of $105.00 from $115.00 previously